Geneva (PRWEB UK) 13 December 2013
UNITAID’s Executive Board has approved over $140 million in new funding. The organisation remains committed to children living with HIV/AIDS and will continue funding treatment for almost 100,000 children in Malawi, Mozambique and Uganda. Additional investments have been targeted to further stabilize the paediatric HIV treatment market. UNITAID will also continue funding for existing projects to shape markets for HIV/AIDS, malaria and tuberculosis.
Funding of $30 million is provided for Malawi, Mozambique and Uganda for paediatric HIV treatment until 2015 and $12.6 million has been allocated to ensure better coordination for the paediatric HIV medicines market.
“More investment in paediatric HIV treatment is still needed, despite our huge success in creating incentives for companies to develop treatment for children living with HIV in low-income countries,” said Dr Philippe Douste-Blazy, Chairman of the UNITAID Executive Board. “Until the day when no child is born with HIV, UNITAID will remain committed to the right of children living with the virus to lead healthy, normal lives.”
One of UNITAID’s initial investments in 2006 was to develop paediatric HIV treatments for low-income countries. Now that price reductions of 80% have been achieved for child-friendly formulations, 37 countries previously supported by UNITAID have managed to successfully finance their own paediatric HIV programmes from other sources.
“The UNITAID commitments made today to Malawi, Mozambique and Uganda will enable these countries to have their funding transitioned to other sources in 2015,” said Dr Denis Broun, Executive Director of UNITAID.
Finally, UNITAID has approved a $50 million extension to the World Health Organization (WHO) Prequalification Programme for Medicines and Diagnostics, an essential service that guarantees quality drugs for low-income countries and opens their markets to low-cost generic producers.
Note to Editors:
The new UNITAID funding commitments also include: